Cysteinyl leukotriene interactions with other mediators and with glucocorticosteroids during airway inflammation

Journal of Allergy and Clinical Immunology

Volumn 111, Issue 1 SUPPL., 2003, Pages

  Peters Golden, Marc ^a   Sampson, Anthony P ^b   Henderson, William ^c   Holgate, Stephen ^c   Liu, Mark ^c   Moqbel, Redwan ^c   Bisgaard, Hans ^c   Peters, Stephen ^c   Panettieri, Reynold ^c   Hamid, Qutayba ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c 6301 MSRB III ^*

Author keywords

Asthmatic airway; Cysteinyl leukotrienes; Glucocorticosteroids; Leukocytes

Indexed keywords

GLUCOCORTICOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PEPTIDOLEUKOTRIENE;

ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; ENZYME INDUCTION; GENE DISRUPTION; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; MEDIATOR RELEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION;

EID: 0037249234     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2003.23     Document Type: Conference Paper

References (44)

1. Tohda Y, Nakahara H, Kubo H, et al. Effects of ONO-1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma. Clin Exp Allergy 1999;29:1532-6.
2. Nag S, Lamkhioued B, Renzi PM. Interleukin-2-induced increased airway responsiveness and lung Th2 cytokine expression occur after antigen challenge through the leukotriene pathway. Am J Respir Crit Care Med 2002;165:1540-5.
3. Underwood DC, Osborn RR, Newsholme SJ, et al. Persistent airway eosinophilia after leukotriene (LT) D4 administration in the guinea pig: modulation by the LTD4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody. Am J Respir Crit Care Med 1996;154:850-7.
4. Macfarlane AJ, Ying S, Smith SJ, et al. Inhibition of allergen-induced late phase reactions by zarfirlukast and beclomethasone may be mediated by attentuation of eotaxin- and RANTES-mediated eosinophil recruitment [abstract]. Am J Respir Crit Care Med 2000;161:A834.
5. Peters-Golden M, Bailie M, Marshall T, et al. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 2002;165:229-35.
6. Patrignani P, Modica R, Bertolero F, et al. Differential effects of leukotriene C4 on endothelin-1 and prostacyclin release by cultured vascular cells. Pharmacol Res 1993;27:281-5.
7. Menard G, Bissonnette EY. Priming of alveolar macrophages by leukotriene D(4): potentiation of inflammation. Am J Respir Cell Mol Biol 2000;23:572-7.
8. Pedersen KE, Bochner BS, Undem BJ. Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a non-CysLT1 receptor-mediated mechanism. J Pharmacol Exp Ther 1997;281:655-62.
9. Calhoun WJ, Lavins BJ, Minkwitz MC, et al. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med 1998;157:1381-9.
10. Hojo M, Suzuki M, Maghni K, et al. Role of cysteinyl leukotrienes in CD4(+) T cell-driven late allergic airway responses. J Pharmacol Exp Ther 2000;293:410-6.
11. Rajah R, Nunn SE, Herrick DJ, et al. Leukotriene D4 induces MMP-1. which functions as an IGFBP protease in human airway smooth muscle cells. Am J Physiol 1996;271:L1014-22.
12. Bisgaard H, Loland L, Oj JA. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999;160:1227-31.
13. Pynaert G, Grooten J, van Deventer SJ, et al. Cysteinyl leukotrienes mediate histamine hypersensitivity ex vivo by increasing histamine receptor numbers. Mol Med 1999;5:685-92.
14. Cowburn AS, Holgate ST, Sampson AP. IL-5 increases expression of 5-lipoxygenase-activating protein and translocates 5-lipoxygenase to the nucleus in human blood eosinophils. J Immunol 1999;163:456-65.
15. Hsieh FH, Lam BK, Penrose JF, et al. T helper cell type 2 cytokines coordinately regulate immunoglobulin E-dependent cysteinyl leukotriene production by human cord blood-derived mast cells: profound induction of leukotriene c(4) synthase expression by interleukin 4. J Exp Med 2001;193:123-34.
16. Brock TG, McNish RW, Coffey MJ, et al. Effects of granulocyte-macrophage colony-stimulating factor on eicosanoid production by mononuclear phagocytes. J Immunol 1996;156:2522-7.
17. Steinhilber D, Radmark O, Samuelsson B. Transforming growth factor beta upregulates 5-lipoxygenase activity during myeloid cell maturation. Proc Natl Acad Sci U S A 1993;90:5984-8.
18. Yamamura H, Nabe T, Kohno S, et al. Endothelin-1 induces release of histamine and leukotriene C4 from mouse bone marrow-derived mast cells. Eur J Pharmacol 1994;257:235-42.
19. Hisada T, Salmon M, Nasuhara Y, et al. Cysteinyl-leukotrienes partly mediate eotaxin-induced bronchial hyperresponsiveness and eosinophilia in IL-5 transgenic mice. Am J Respir Crit Care Med 1999;160:571-5.
20. Rais M, Corry D. IL-13 is required in 5-lipoxygenase mediated allergic inflammation in experimental asthma [abstract]. Am J Respir Crit Care Med 2001;163:A434.
21. Coffey MJ, Phare SM, Peters-Golden M. Prolonged exposure to lipopolysaccharide inhibits macrophage 5- lipoxygenase metabolism via induction of nitric oxide synthesis. J Immunol 2000;165:3592-8.
22. Thivierge M, Stankova J, Rola-Pleszczynski M. 11-13 and 11-4 up-regulate cysteinyl leukotriene 1 receptor expression in human monocytes and macrophages. J Immunol 2001;167:2855-60.
23. Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 1993;14:436-41.
24. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 1999;160:1862-8.
25. Sebaldt RJ, Sheller JR, Oates JA, et al. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci U S A 1990;87:6974-8.
26. Manso G, Baker AJ, Taylor IK, et al. In vivo and in vitro effects of glucocorticosteroids on arachidonic acid metabolism and monocyte function in nonasthmatic humans. Eur Respir J 1992;5:712-6.
27. O'Shaughnessy KM, Wellings R, Gillies B, et al. Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion. Am Rev Respir Dis 1993;147:1472-6.
28. Powell WS, Xu LJ, Martin JG. Effects of dexamethasone on leukotriene synthesis and airway responses to antigen and leukotriene D4 in rats. Am J Respir Crit Care Med 1995;151:1143-50.
29. Dworski R, Fitzgerald GA, Oates JA, et al. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994;149:953-9.
30. Oosterhoff Y, Overbeek SE, Douma J, et al. Lower leukotriene C4 levels in bronchoalveolar lavage fluid of asthmatic subjects after 2.5 years of inhaled corticosteroid therapy. Mediat Inflamm 1995;4:426-30.
31. Peters-Golden M, Thebert P. Inhibition by methylprednisolone of zymosan-induced leukotriene synthesis in alveolar macrophages. Am Rev Respir Dis 1987;135:1020-6.
32. Fuller RW, Kelsey CR, Cole PJ, et al. Dexamethasone inhibits the production of thromboxane B2 and leukotriene B4 by human alveolar and peritoneal macrophages in culture. Clin Sci (Lond) 1984;67:653-6.
33. Balter MS, Eschenbacher WL, Peters-Golden M. Arachidonic acid metabolism in cultured alveolar macrophages from normal, atopic, and asthmatic subjects. Am Rev Respir Dis 1988;138:1134-42.
34. De Caterina R, Sicari R, Giannessi D, et al. Macrophage-specific eicosanoid synthesis inhibition and lipocortin-1 induction by glucocorticoids. J Appl Physiol 1993;75:2368-75.
35. Linden M. The effects of beta 2-adrenoceptor agonists and a corticosteroid, budesonide, on the secretion of inflammatory mediators from monocytes. Br J Pharmacol 1992;107:156-60.
36. Schleimer RP, Freeland HS, Peters SP, et al. An assessment of the effects of glucocorticoids on degranulation, chemotaxis, binding to vascular endothelium and formation of leukotriene B4 by purified human neutrophils. J Pharmacol Exp Ther 1989;250:598-605.
37. Peters SP, Naclerio RM, Schleimer RP, et al. The pharmacologic control of mediator release from human basophils and mast cells. Respiration 1986;50:116-22.
38. Pouliot M, McDonald PP, Borgeat P, et al. Granulocyte/macrophage colony-stimulating factor stimulates the expression of the 5-lipoxygenase-activating protein (FLAP) in human neutrophils. J Exp Med 1994;179:1225-32.
39. Goppelt-Struebe M, Schaefer D, Habenicht AJ. Differential regulation of cyclo-oxygenase-2 and 5-lipoxygenase- activating protein (FLAP) expression by glucocorticoids in monocytic cells. Br J Pharmacol 1997;122:619-24.
40. Riddick CA, Ring WL, Baker JR, et al. Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells. Eur J Biochem 1997;246:112-8.
41. Macfarlane AJ, Dworski R, Sheller JR, et al. Sputum cysteinyl leukotrienes increase 24 hours after allergen inhalation in atopic asthmatics. Am J Respir Crit Care Med 2000;161:1553-8.
42. Djukanovic R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992;145:669-74.
43. Tanizaki Y, Kitani H, Okazaki M, et al. Changes in the proportions of bronchoalveolar lymphocytes, neutrophils and basophdic cells and the release of histamine and leukotrienes from bronchoalveolar cells in patients with steroid-dependent intractable asthma. Int Arch Allergy Immunol 1993;101:196-202.
44. Sampson AP. The role of eosinophils and neutrophils in inflammation. Clin Exp Allergy 2000;30:22-7.